NuCana Granted Composition-of-Matter Patent for NUC-7738 in China
NuCana plc has received a composition-of-matter patent for NUC-7738 from the China National Intellectual Property Administration. This patent protects the chemical structure of NUC-7738, an anti-cancer agent in clinical trials with pembrolizumab for melanoma patients resistant to PD-1 inhibitors. The patent aims to enhance global intellectual property protection for NUC-7738 and promote innovative cancer therapies in China.
NuCana plc announced that the China National Intellectual Property Administration has granted a composition-of-matter patent for NUC-7738. This patent covers the chemical structure of NUC-7738, an anti-cancer agent currently being evaluated in clinical studies in combination with pembrolizumab for patients with PD-1 inhibitor refractory or resistant melanoma. The new patent is expected to strengthen the global intellectual property protection for NUC-7738 and support opportunities for innovative cancer therapies in China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568539-en) on November 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
